C3 hybrid aptamer with PSMA-617 pharmacophore (from Pluvicto drug) targeting for PSMA Aptamer Details

ID# 9652

Back to Search Results

Structure

Chemistry

DNA

Target

Prostate-specific membrane antigen (PSMA)

Sequence (3-char table code)

G A C U/T

5'-dGpdGpdApdTpdCpdGpdTpdCpdApdGpdTpdGpdCpdApdTpdTpdGpdApdGpdApdGpdApdApdTpdApdApdTpdApdApdGpdTpdApdApdApdTpdTpdGpdGpdApdApdCpdTpdApdTpdApdApdApdGpdTpdTpdGpdApdApdApdGpdTpdTpdGpdTpdGpdGpdTpdGpdGpdTpdApdTpdCpdCpdGpdCpdApdApdCpdGpdGpdGpdTpdAp-3'

Molecular Weight: 24668.1 g/mole

Extinction Coefficient: 814100

Binding Conditions / Buffer

Binding buffer: 120 mM NaCl, 5 mM MgCl2, 5 mM KCl, 40 mM HEPES pH 7.4.

Binding Temp: 25°C

Refolding Protocol

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Reference

Liu, K., Robinson, N., Tekoglu, E., Lozada, J., Yu, I. P. L., Tai, R. A., Ozturan, D., Dikbas, U. M., Lack, N. A., Cox, M. E., Mannas, M. P., Cohen, P., Goldenberg, S. L., & Perrin, D. M. (2025). Baited SELEX: Drug-Directed Selection of Aptamers to PSMA for in vivo targeting of prostate cancer xenografts in mice. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c13307

Request a Quote Have your aptamer oligo synthesized by Aptagen.